Publications by authors named "Dolores M Shoback"

Article Synopsis
  • Conventional therapy for hypoparathyroidism helps with hypocalcemia symptoms but doesn't fix low parathyroid hormone (PTH) levels; TransCon PTH (palopegteriparatide) is being studied as a potential long-term treatment.
  • A Phase 3 trial involved 82 adults across 21 sites in North America and Europe, with participants receiving TransCon PTH daily during a 156-week open-label period after an initial 26-week placebo-controlled phase.
  • Results showed that by week 52, 81% of participants achieved normal serum calcium levels without needing conventional therapy, improved their quality of life, and experienced mostly mild to moderate side effects, indicating the treatment's sustained efficacy and safety.
View Article and Find Full Text PDF
Article Synopsis
  • Individuals with chronic hypoparathyroidism on traditional therapy have a higher risk of kidney problems, and new treatments like palopegteriparatide could help improve kidney function while reducing reliance on conventional treatments.
  • The PaTHway trial assessed the effects of palopegteriparatide on renal function over 52 weeks, showing promising results such as improved eGFR levels.
  • After a year of treatment, many participants achieved normal calcium levels and stopped needing traditional therapies, with significant improvements in kidney function, especially in those with lower baseline eGFR.
View Article and Find Full Text PDF

Context: Chronic hypoparathyroidism is conventionally treated with oral calcium and active vitamin D to reach and maintain targeted serum calcium and phosphorus levels, but some patients remain inadequately controlled.

Objective: To assess long-term safety and efficacy of recombinant human parathyroid hormone (1-84) (rhPTH(1-84)) treatment.

Methods: This was an open-label extension study at 12 US centers.

View Article and Find Full Text PDF
Article Synopsis
  • - Conventional therapy for hypoparathyroidism, which includes active vitamin D and calcium, doesn't address the underlying issue of parathyroid hormone (PTH) deficiency, making PTH replacement therapy an ideal treatment option.
  • - The PaTHway trial tested the efficacy of the investigational drug TransCon PTH over 26 weeks, showing that 79% of participants on TransCon PTH reached normal serum calcium levels and could stop conventional therapy, compared to only 5% on placebo.
  • - TransCon PTH significantly improved participants' quality of life and symptoms related to hypoparathyroidism, with a notable percentage achieving independence from traditional treatments and normal urinary calcium levels.
View Article and Find Full Text PDF

The approach utilized a systematic review of the medical literature executed with specifically designed criteria that focused on the etiologies and pathogenesis of hypoparathyroidism. Enhanced attention by endocrine surgeons to new knowledge about parathyroid gland viability are reviewed along with the role of intraoperative parathyroid hormone (ioPTH) monitoring during and after neck surgery. Nonsurgical etiologies account for a significant proportion of cases of hypoparathyroidism (~25%), and among them, genetic etiologies are key.

View Article and Find Full Text PDF

This clinical practice guideline addresses the prevention, diagnosis, and management of hypoparathyroidism (HypoPT) and provides evidence-based recommendations. The HypoPT task forces included four teams with a total of 50 international experts including representatives from the sponsoring societies. A methodologist (GG) and his team supported the taskforces and conducted the systematic reviews.

View Article and Find Full Text PDF

Fracture risk is increased in type 2 diabetes, which may in part be due to altered bone marrow adiposity. Cross sectional studies have reported that people with type 2 diabetes have lower unsaturated BMAT lipid levels than people without diabetes, although there are limited data on longitudinal changes. We hypothesized that Roux-en-Y gastric bypass (RYGB), which dramatically improves glycemic status, would have differential effects on BMAT composition, with increases in the unsaturated lipid index in people with diabetes.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to explore the relationship between rheumatoid arthritis (RA) disease activity and bone mineral density (BMD), specifically whether cumulative RA disease activity is linked to BMD levels.
  • - Researchers analyzed data from 161 RA participants over 12 years, revealing that lower disease activity was associated with higher BMD at the femoral neck, independent of usual osteoporosis risk factors.
  • - Findings indicate that maintaining low cumulative disease activity can positively impact bone health in RA patients, with consistent results even when using different measures of disease activity and other BMD sites.
View Article and Find Full Text PDF

Importance: Primary hyperparathyroidism (PHPT) contributes to the development and progression of osteoporosis in older adults. The effectiveness of parathyroidectomy for reducing fracture risk in older adults is unknown.

Objective: To compare the incidence of clinical fracture among older adults with PHPT treated with parathyroidectomy vs nonoperative management.

View Article and Find Full Text PDF

Background: The PARADIGHM registry of adult and pediatric patients with chronic hypoparathyroidism evaluates the long-term safety and effectiveness of treatment with recombinant human parathyroid hormone, rhPTH(1-84), and describes the clinical disease course under conditions of routine clinical practice. In this first report, we detail the registry protocol and describe the baseline characteristics of two adult patient cohorts from an interim database analysis. One cohort after study entry were prescribed rhPTH(1-84), and the other cohort received conventional therapy of calcium and active vitamin D.

View Article and Find Full Text PDF
Sporadic Primary Hyperparathyroidism.

Endocrinol Metab Clin North Am

December 2021

Sporadic primary hyperparathyroidism is a common endocrinopathy, particularly afflicting postmenopausal women and both African American men and women. Although classic signs and symptoms of the disease are well appreciated and described, because of the ease and availability and low threshold for screening, the disorder often is diagnosed in patients who are minimally symptomatic or asymptomatic. Surgery conducted by experienced endocrine surgeons has a high cure rate, particularly if guided by concordant imaging.

View Article and Find Full Text PDF

Purpose Of Review: Rheumatoid arthritis (RA) is associated with increased risk for osteoporotic fracture. We highlight RA-specific risk factors for bone mineral density (BMD) loss and fractures and considerations regarding the diagnosis and treatment of osteoporosis in patients with RA.

Recent Findings: Anticitrullinated protein antibody (ACPA) positivity, although associated with low BMD in early RA, is not associated with accelerated BMD loss over time when compared to ACPA negative individuals.

View Article and Find Full Text PDF

More informed discussions between physicians and older adults about the consequences of an initial osteoporotic fracture could encourage more patients to consider treatments that protect against future fracture.

View Article and Find Full Text PDF

Molecular mechanisms mediating tonic secretion of parathyroid hormone (PTH) in response to hypocalcaemia and hyperparathyroidism (HPT) are unclear. Here we demonstrate increased heterocomplex formation between the calcium-sensing receptor (CaSR) and metabotropic γ-aminobutyric acid (GABA) B receptor (GABAR) in hyperplastic parathyroid glands (PTGs) of patients with primary and secondary HPT. Targeted ablation of GABAR or glutamic acid decarboxylase 1 and 2 in PTGs produces hypocalcaemia and hypoparathyroidism, and prevents PTH hypersecretion in PTGs cultured from mouse models of hereditary HPT and dietary calcium-deficiency.

View Article and Find Full Text PDF

Objectives: Frailty in the general population is associated with poor health outcomes including low bone mass and osteoporotic fracture. The relationship between frailty and low bone mineral density (BMD) in rheumatoid arthritis (RA) is unknown. This study examined associations between frailty and BMD in RA, controlling for established osteoporosis risk factors.

View Article and Find Full Text PDF

Context: The gut hormones peptide YY (PYY) and ghrelin mediate in part the metabolic benefits of Roux-en-Y gastric bypass (RYGB) surgery. However, preclinical data suggest these hormones also affect the skeleton and could contribute to postoperative bone loss.

Objective: We investigated whether changes in fasting serum total PYY and ghrelin were associated with bone turnover marker levels and loss of bone mineral density (BMD) after RYGB.

View Article and Find Full Text PDF

Current osteoporosis medications reduce fractures significantly but have rare and serious adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their safety for long-term use. Insights from basic bone biology and genetic disorders have led to recent advances in therapeutics for osteoporosis. New approaches now in clinical use include the antisclerostin monoclonal antibody romosozumab, as well as the parathyroid hormone-related peptide analog abaloparatide.

View Article and Find Full Text PDF

Calcium and its putative receptor (CaSR) control skeletal development by pacing chondrocyte differentiation and mediating osteoblast (OB) function during endochondral bone formation-an essential process recapitulated during fracture repair. Here, we delineated the role of the CaSR in mediating transition of callus chondrocytes into the OB lineage and subsequent bone formation at fracture sites and explored targeting CaSRs pharmacologically to enhance fracture repair. In chondrocytes cultured from soft calluses at a closed, unfixed fracture site, extracellular [Ca ] and the allosteric CaSR agonist (NPS-R568) promoted terminal differentiation of resident cells and the attainment of an osteoblastic phenotype.

View Article and Find Full Text PDF

Context: Conventional hypoparathyroidism treatment with oral calcium and active vitamin D is aimed at correcting hypocalcemia but does not address other physiologic defects caused by PTH deficiency.

Objective: To evaluate long-term safety and tolerability of recombinant human PTH (1-84) [rhPTH(1-84)].

Design: Open-label extension study; 5-year interim analysis.

View Article and Find Full Text PDF

Context: Bariatric surgery results in reduced muscle mass as weight is lost, but postoperative changes in muscle strength and performance are incompletely understood.

Objective: To examine changes in body composition, strength, physical activity, and physical performance following Roux-en-Y gastric bypass (RYGB).

Design, Participants, Outcomes: In a prospective cohort of 47 adults (37 women, 10 men) aged 45 ± 12 years (mean ± SD) with body mass index (BMI) 44 ± 8 kg/m2, we measured body composition by dual-energy X-ray absorptiometry, handgrip strength, physical activity, and physical performance (chair stand time, gait speed, 400-m walk time) before and 6 and 12 months after RYGB.

View Article and Find Full Text PDF

Familial hypocalciuric hypercalcemia (FHH) causes hypercalcemia by three genetic mechanisms: inactivating mutations in the calcium-sensing receptor, the G-protein subunit α, or adaptor-related protein complex 2, sigma 1 subunit. While hypercalcemia in other conditions causes significant morbidity and mortality, FHH generally follows a benign course. Failure to diagnose FHH can result in unwarranted treatment or surgery for the mistaken diagnosis of primary hyperparathyroidism (PHPT), given the significant overlap of biochemical features.

View Article and Find Full Text PDF

Roux-en-Y gastric bypass (RYGB) surgery is a highly effective treatment for obesity but negatively affects the skeleton. Studies of skeletal effects have generally examined areal bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA), but DXA may be inaccurate in the setting of marked weight loss. Further, as a result of modestly sized samples of mostly premenopausal women and very few men, effects of RYGB by sex and menopausal status are unknown.

View Article and Find Full Text PDF